LDK378 in ALK+ Crizotinib-Resistant NSCLC Patients
Alice T. Shaw, MD, PhD, discusses the results of a trial looking at LDK378 for patients with ALK+ crizotinib-resistant non-small cell lung cancer.
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the results of a trial looking at LDK378 for patients with ALK+ crizotinib-resistant non-small cell lung cancer.
The results of the trial were remarkable, Shaw says, as nearly all patients in this population responded to LDK378.
In the case of EGFR-mutant lung cancer, there has been limited success once patients develop resistance to EGFR inhibitors. Because of this, it was unclear how successful ALK inhibitors would be in their respective space, but researchers were pleasantly surprised.
Clinical Pearls
In the study, about 60% of patients responded, Shaw says. An additional 20-30% responded to treatment with LDK378, though formal criteria for a response was not met.
- Nearly all crizotinib-resistant NSCLC patients responded to LDK378
- EGFR-mutant lung cancer patients have seen limited success following resistance to EGFR inhibitors
- About 60% of crizotinib-resistant patients responded to LDK378, with an additional 20-30% demonstrating some response
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Kim Evaluates New Regimens for EGFR+ Lung Cancer
January 20th 2025During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.
Read More
